Basic Description

Synonyms	Example 1 [US9556146B2] \| BCP32788 \| BDBM50558735 \| BT11 \| BT-11 \| AKOS037515592 \| HY-102013 \| BT 11; BT11 \| GTPL10363 \| CS-7521 \| [4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone \| s6419 \| UN
Specifications & Purity	Moligand™, ≥97%
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Mechanism of action	LanC like 2
Product Description	Information BT-11 is an orally activelanthionine synthetase C-like 2 (LANCL2)binding compound for treating inflammatory bowel disease (IBD) (Kd value of 7.7 µM).

Associated Targets(Human)

LANCL2 Tchem LanC-like protein 2 (0 Activities)

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mus musculus (284745 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

IUPAC Name	[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone
INCHI	InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)
InChi Key	MVHWZNBAQIGPOQ-UHFFFAOYSA-N
Canonical SMILES	C1CN(CCN1C(=O)C2=CC=CC(=N2)C3=NC4=CC=CC=C4N3)C(=O)C5=CC=CC(=N5)C6=NC7=CC=CC=C7N6
Isomeric SMILES	C1CN(CCN1C(=O)C2=CC=CC(=N2)C3=NC4=CC=CC=C4N3)C(=O)C5=CC=CC(=N5)C6=NC7=CC=CC=C7N6
PubChem CID	121299620
Molecular Weight	528.56

PubChem CID	121299620
CAS Registry No.	1912399-75-7

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
I2206405	Certificate of Analysis	Jun 15, 2022	B413444
I2206406	Certificate of Analysis	Jun 15, 2022	B413444
I2206407	Certificate of Analysis	Jun 15, 2022	B413444

1. Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. (2016) An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease.. J Med Chem, 59 (22): (10113-10126). [PMID:27933891] [10.1021/op500134e]
2. Bissel P, Boes K, Hinckley J, Jortner BS, Magnin-Bissel G, Werre SR, Ehrich M, Carbo A, Philipson C, Hontecillas R et al.. (2016) Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease.. Int J Toxicol, 35 (5): (521-9). [PMID:27230993] [10.1021/op500134e]
3. Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bassaganya-Riera J. (2018) Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.. Inflamm Bowel Dis, 24 (9): (1978-1991). [PMID:29718324] [10.1021/op500134e]
4. Leber A, Hontecillas R, Zoccoli-Rodriguez V, Chauhan J, Bassaganya-Riera J. (2019) Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the Gut.. J Immunol, 202 (7): (2095-2104). [PMID:30760618] [10.1021/op500134e]

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price
B413444-5mg	5mg	In stock	$339.90
B413444-25mg	25mg	In stock	$1,042.90
B413444-100mg	100mg	In stock	$3,433.90